13F Pro13F Pro

ORBIMED ADVISORS LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1055951
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare99.4%$5.2B
  • Energy0.6%$30.3M
  • Other0.0%$1.1M

AUM History

13fpro.ai/research/fund/orbimed-advisors-llc-1055951

Conviction and streaks

Stable · top 10 = 43.0%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

EWTX$EWTXConviction hold11.9% weight · held 10 quartersELVN$ELVNConviction hold6.5% weight · held 10 quartersLLY$LLYConviction hold5.9% weight · held 10 quartersMBX$MBXConviction hold3.6% weight · held 8 quartersSVA$SVAConviction hold3.5% weight · held 10 quartersGPCR$GPCRAccumulating+94% shares · 3 quarters runningRYTM$RYTMAccumulating+50% shares · 3 quarters runningPRAX$PRAXAccumulating+144% shares · 2 quarters runningABVX$ABVXAccumulating+49% shares · 2 quarters runningDYN$DYNAccumulating+47% shares · 2 quarters runningALNY$ALNYTrimming-96% shares · 6 quarters runningARGX$ARGXTrimming-55% shares · 4 quarters runningBSX$BSXTrimming-47% shares · 4 quarters runningISRG$ISRGTrimming-46% shares · 4 quarters runningMBX$MBXTrimming-14% shares · 3 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/orbimed-advisors-llc-1055951

ORBIMED ADVISORS LLC 13F holdings — Q2 2026

$5.4B portfolio (+7.0% QoQ) · 129 holdings · Q2 2026 13F · top 10 are 43% of the stock portfolio

Includes $117.4M of put/call options ($48.8M puts, $68.5M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $5.3B. Weights use the stock portfolio.

All holdings — ORBIMED ADVISORS LLC (Q2 2026)

129 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
GH$GHGuardant Health, Inc.$87.6M+34%
ARGX$ARGXARGENX SEadr$86.2M-32%
MRK$MRKMerck & Co., Inc.$85.2M—
QURE$QUREuniQure N.V.$83.3M-15%
PRAX$PRAXPraxis Precision Medicines, Inc.$77.0M+33%
EW$EWEdwards Lifesciences Corp$75.5M-32%
PRLD$PRLDPrelude Therapeutics Inc$73.2M+26%
ABVX$ABVXAbivax S.A.adr$72.8M+17%
DYN$DYNDyne Therapeutics, Inc.$71.9M+11%
NTRA$NTRANatera, Inc.$71.1M—
CGON$CGONCG Oncology, Inc.$69.1M+3%
UNH$UNHUNITEDHEALTH GROUP INC$67.0MNew
SPRY$SPRYARS Pharmaceuticals, Inc.$66.4M—
ASND$ASNDAscendis Pharma A/S$65.2M+34%
HUM$HUMHUMANA INC$65.2MNew

What changed in Q2 2026

Against the previous quarter's 13F: 40 new, 33 added to, 27 trimmed, 24 sold out. Share-count changes; largest moves by dollar size first.

New positions (40)

  • UNH$UNHUNITEDHEALTH GROUP INC$67.0M

    first bought this quarter

  • HUM$HUMHUMANA INC$65.2M

    first bought this quarter

  • ODTX$ODTXOdyssey Therapeutics, Inc.$56.2M

    first bought this quarter

  • ARQT$ARQTArcutis Biotherapeutics, Inc.$53.5M

    first bought this quarter

  • PUTSPDR SERIES TRUST - ST STR SP BIOT$47.5M

    first bought this quarter

  • ABVX$ABVXCALLAbivax S.A.$26.7M

    first bought this quarter

+34 more in the Excel export

Added to (33)

  • COGT$COGTCogent Biosciences, Inc.+422%

    now $65.1M · held 3 qtrs

  • AZN$AZNASTRAZENECA PLC+37%

    now $171.1M · held 2 qtrs, 2 adds in a row

  • GPCR$GPCRStructure Therapeutics Inc.+50%

    now $118.6M · held 6+ qtrs, 3 adds in a row

  • LLY$LLYELI LILLY & Co+9%

    now $309.3M · held 6+ qtrs

  • PVLA$PVLAPALVELLA THERAPEUTICS, INC.+117%

    now $44.7M · held 2 qtrs, 2 adds in a row

  • QTTB$QTTBQ32 Bio Inc.+83%

    now $52.6M · held 6+ qtrs

+27 more in the Excel export

Trimmed (27)

  • ELVN$ELVNEnliven Therapeutics, Inc.-15%

    now $343.9M · held 6+ qtrs

  • IRON$IRONDisc Medicine, Inc.-67%

    now $26.2M · held 6+ qtrs

  • SION$SIONSionna Therapeutics, Inc.-28%

    now $112.4M · held 6+ qtrs

  • ARGX$ARGXARGENX SE-32%

    now $86.2M · held 6+ qtrs, 4 trims in a row

  • BSX$BSXBOSTON SCIENTIFIC CORP-38%

    now $63.3M · held 6+ qtrs, 2 trims in a row

  • EW$EWEdwards Lifesciences Corp-32%

    now $75.5M · held 6+ qtrs, 2 trims in a row

+21 more in the Excel export

Sold out (24)

  • MDXH$MDXHCALLMDxHealth SAwas $285.9M
  • RCEL$RCELCALLAVITA Medical, Inc.was $154.4M
  • MYGN$MYGNMYRIAD GENETICS INCwas $122.9M

    held 1 qtr

  • PFE$PFEPFIZER INCwas $54.7M

    held 2 qtrs

  • DHR$DHRDANAHER CORP /DE/was $50.4M

    held 3 qtrs

  • RCEL$RCELAVITA Medical, Inc.was $42.5M

    held 1 qtr

+18 more in the Excel export

Firm AUM (Form ADV): $20.6B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F ORBIMED ADVISORS LLC has filed, 41 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow ORBIMED ADVISORS?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 27, 2026.

Average quality of ORBIMED ADVISORS's top 20 holdings: 67/100 (our AI quality score, weighted by position size; 6 of the 20 are scored)

Top 10 since filing

-17.0%

Value-weighted move of the 10 largest stock positions

Turnover

18%

Last quarter; 60% over the last 4

Top 10 weight

43%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

72%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

ORBIMED ADVISORS LLC disclosed 129 positions worth $5.4B in its Form 13F-HR for Q2 2026 — $5.3B in common stock plus $117.4M of put/call option positions (reported at underlying notional value, not premium at risk), led by $EWTX (Edgewise Therapeutics, Inc.) at 11.9% of the equity portfolio, followed by $ELVN and $LLY. During the quarter the fund opened 40 new positions and exited 24 — including a new stake in $UNH and a full exit from $MDXH. The portfolio is most concentrated in Healthcare (99.4% of disclosed assets). All figures are sourced directly from ORBIMED ADVISORS LLC’s Form 13F-HR filing with the SEC under CIK 1055951.

Funds like this

managers whose biggest positions overlap ORBIMED ADVISORS's
Novo Holdings A/S$1.72B 13F book · 5 shared top holdingsEWTXELVNAVBPDYNVestal Point Capital, LP$4.28B 13F book · 7 shared top holdingsELVNAZNABVXDYNRA CAPITAL MANAGEMENT, L.P.$11.51B 13F book · 5 shared top holdingsEWTXSIONABVXMLYSLogos Global Management LP$2.32B 13F book · 10 shared top holdingsABVXAVBPPRAXDYNSiren, L.L.C.$4.94B 13F book · 8 shared top holdingsEWTXELVNABVXCOGTBRAIDWELL LP$2.70B 13F book · 8 shared top holdingsEWTXMBXHUMCRVS

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: ORBIMED ADVISORS LLC

13F Pro is an AI hedge fund tracker and stock research platform. For ORBIMED ADVISORS LLC (SEC CIK: 1055951), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in ORBIMED ADVISORS LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.